Egetis Therapeutics

Governance Information • Dec 22, 2020

PRESSMEDDELANDE

Egetis Therapeutics AB Stockholm, Sweden, December 22, 2020

Nomination Committee appointed for the 2021 Annual General Meeting in Egetis Therapeutics

Stockholm, Sweden, December 22, 2020. The Chairman of Egetis Therapeutics AB has established a Nomination Committee for the Annual General Meeting, which is planned to be held on April 29, 2021. The Nomination Committee is composed of members appointed by the three largest shareholders in terms of voting rights, that have accepted the invitation to join the committee.

The following members have been appointed by the subsequent shareholders: Avla Holding AB: Kenneth Rooth Fjärde AP-fonden: Jannis Kitsakis Cidro Förvaltning AB: Peter Lindell

The Nomination Committee has elected Kenneth Rooth as chairman. Håkan Åström, Chairman of the Board of Directors, has been nominated to co-opt to the Nomination Committee.

In total, the Nomination Committee represents approx. 26% of the total number of shares and votes in the company. All representatives are independent in relation to the company and its executive management. Peter Lindell and Jannis Kitsakis are also independent in relation to Cetoros AB, which is the largest shareholder in the company in terms of votes but has declined participation in the committee.

The Committee's assignment is to present proposals regarding Chairman and other members of the Board, as well as remuneration to the Board´s members, to the Annual General Meeting (AGM). The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals regarding the process to appoint the Nomination Committee for the AGM in 2022.

Shareholders who wish to submit proposals to the Nomination Committee can do so by email: hakanastrom@aol.com

For further information, please contact:

Marie-Louise Alamaa, Interim CFO Tel. +46 (0) 70 861 88 42 Email: marie-louise.alamaa@egetis.com.

The information was submitted for publication, through the agency of the contact person set out above, at 2020-12-22, 16:00 CET.

About Egetis Therapeutics

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment. The drug candidate Emcitate® is a first in class drug candidate developed for the treatment of MCT8 deficiency, a rare disease with high unmet medical need and no available treatment. A Phase IIb clinical trial was completed with significant and clinically relevant effects. A pivotal Phase IIb/III early intervention study was initiated in Dec 2020 with the first patient dosed and interim results is planned for 2022.

Emcitate holds Orphan Drug Designation in the US and EU and was granted Pediatric Disease designation by the US FDA in November 2020. The drug candidate Aladote® is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for Aladote has been finalized after completed interactions with FDA, EMA and MHRA. Aladote® has been granted Orphan Drug Designation in the US. Results from the PledOx POLAR program in Dec 2020 shows that Pledox did not meet the efficacy endpoint. Based on further evaluation of the results from the POLAR studies, the strategic next steps for PledOx® will be determined together with our partner Solasia.

Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see www.egetis.com